Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b, Multicenter Study to Determine the Dose, Safety, Efficacy and Pharmacokinetics of TRK-950 When Used in Combinations With Selected Anti-Cancer Treatment Regimens in Patients With Selected Advanced Solid Tumors

NCT03872947 is registered in ClinicalTrials.gov with Toray Industries, Inc as lead sponsor.

NCT NCT03872947
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03872947 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b, Multicenter Study to Determine the Dose, Safety, Efficacy and Pharmacokinetics of TRK-950 When Used in Combinations With Selected Anti-Cancer Treatment Regimens in Patients With Selected Advanced Solid Tumors
Lead sponsor
Toray Industries, Inc
Phase
Phase 1
Overall status
Completed
Start date
April 26, 2019
Completion date
July 16, 2026
Enrollment
138 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

bladder cancer, cholangiocarcinoma, colorectal cancer, epithelial ovarian cancer, fallopian tube cancer, gastric cancer, melanoma, ovarian cancer, palpable subcutaneous malignant lesions, primary peritoneal cancer, renal cell carcinoma, solid tumor